Zobrazeno 1 - 4
of 4
pro vyhledávání: ''
Autor:
Mark Clemons, Rachel Anne Goodwin, A Imbulgoda, Tharshika Thangarasa, Patricia A. Tang, Joanna Gotfrit, Michael M. Vickers
Publikováno v:
Current Oncology. 26:162-166
Background The optimal management of hypomagnesemia (hMg) induced by epidermal growth factor receptor inhibitors (egfris) for advanced colorectal cancer is unclear. We surveyed gastrointestinal medical oncologists in Canada to determine practice patt
Autor:
Vera Hirsh, S. Morin–Ben Abdallah
Publikováno v:
Current Oncology. 25:9-17
Despite recent advances in the systemic therapy of non-small-cell lung cancer (NSCLC), the prognosis for stage IV disease remains poor. The discovery of targetable mutations has led to new treatment options. The most common mutations, the EGFR activa
Autor:
A Azad, K. Hui, Ellen Warner, S Ahmed, S Sridhar, D C Hodgson, K Morarji, O McArdle, Ellen M. Greenblatt, A M F Ali, G Gingras-Hill
Publikováno v:
Current Oncology
Volume 24
Issue 6
Pages 3335-502
Volume 24
Issue 6
Pages 3335-502
As cure rates for breast cancer improve, there is increasing evidence that late effects of treatment&mdash
and impaired fertility in particular&mdash
are emerging as important concerns among young breast cancer survivors. Older reports have
and impaired fertility in particular&mdash
are emerging as important concerns among young breast cancer survivors. Older reports have
Autor:
Donald R. Walkinshaw, Xiang-Jiao Yang
Publikováno v:
Current Oncology
Volume 15
Issue 5
Pages 371-243
Volume 15
Issue 5
Pages 371-243
Histone deacetylase inhibitors represent a promising new class of compounds for the treatment of cancer. Inhibitors of this kind currently under clinical evaluation mainly target the classical (Rpd3/Hda1) family of histone deacetylases. Of particular